178 related articles for article (PubMed ID: 22033823)
21. β-Glucocerebrosidase Deficiency Activates an Aberrant Lysosome-Plasma Membrane Axis Responsible for the Onset of Neurodegeneration.
Lunghi G; Carsana EV; Loberto N; Cioccarelli L; Prioni S; Mauri L; Bassi R; Duga S; Straniero L; Asselta R; Soldà G; Di Fonzo A; Frattini E; Magni M; Liessi N; Armirotti A; Ferrari E; Samarani M; Aureli M
Cells; 2022 Jul; 11(15):. PubMed ID: 35954187
[TBL] [Abstract][Full Text] [Related]
22. Activity-Based Probes for Glycosidases: Profiling and Other Applications.
Kuo CL; van Meel E; Kytidou K; Kallemeijn WW; Witte M; Overkleeft HS; Artola ME; Aerts JM
Methods Enzymol; 2018; 598():217-235. PubMed ID: 29306436
[TBL] [Abstract][Full Text] [Related]
23. Lysosomal degradation on vesicular membrane surfaces. Enhanced glucosylceramide degradation by lysosomal anionic lipids and activators.
Wilkening G; Linke T; Sandhoff K
J Biol Chem; 1998 Nov; 273(46):30271-8. PubMed ID: 9804787
[TBL] [Abstract][Full Text] [Related]
24. L-glucosylceramide: synthesis, properties, and resistance to catabolism by glucocerebrosidase in vitro.
Gal AE; Pentchev PG; Massey JM; Brady RO
Proc Natl Acad Sci U S A; 1979 Jul; 76(7):3083-6. PubMed ID: 290986
[TBL] [Abstract][Full Text] [Related]
25. Lipids regulate the hydrolysis of membrane bound glucosylceramide by lysosomal β-glucocerebrosidase.
Abdul-Hammed M; Breiden B; Schwarzmann G; Sandhoff K
J Lipid Res; 2017 Mar; 58(3):563-577. PubMed ID: 28126847
[TBL] [Abstract][Full Text] [Related]
26. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
[TBL] [Abstract][Full Text] [Related]
27. Identification of ß-Glucocerebrosidase Activators for Glucosylceramide hydrolysis.
Schulze MED; Scholz D; Jnoff E; Hall A; Melin J; Sands ZA; Rodriguez E; Andre VM
ChemMedChem; 2024 Apr; 19(7):e202300548. PubMed ID: 38381042
[TBL] [Abstract][Full Text] [Related]
28. Fluorescent flow cytometric assay: a new diagnostic tool for measuring beta-glucocerebrosidase activity in Gaucher disease.
Rudensky B; Paz E; Altarescu G; Raveh D; Elstein D; Zimran A
Blood Cells Mol Dis; 2003; 30(1):97-9. PubMed ID: 12667991
[TBL] [Abstract][Full Text] [Related]
29. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
Trapero A; Llebaria A
Future Med Chem; 2013 Apr; 5(5):573-90. PubMed ID: 23573974
[TBL] [Abstract][Full Text] [Related]
30. Glycosphingolipid analysis in a naturally occurring ovine model of acute neuronopathic Gaucher disease.
Karageorgos L; Hein L; Rozaklis T; Adams M; Duplock S; Snel M; Hemsley K; Kuchel T; Smith N; Hopwood JJ
Neurobiol Dis; 2016 Jul; 91():143-54. PubMed ID: 26976737
[TBL] [Abstract][Full Text] [Related]
31. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.
Mazzulli JR; Xu YH; Sun Y; Knight AL; McLean PJ; Caldwell GA; Sidransky E; Grabowski GA; Krainc D
Cell; 2011 Jul; 146(1):37-52. PubMed ID: 21700325
[TBL] [Abstract][Full Text] [Related]
32. Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.
Ivanova MM; Dao J; Kasaci N; Adewale B; Nazari S; Noll L; Fikry J; Sanati AH; Goker-Alpan O
PLoS One; 2021; 16(10):e0247211. PubMed ID: 34695170
[TBL] [Abstract][Full Text] [Related]
33. A sensitive and reproducible fluorescent-based HPLC assay to measure the activity of acid as well as neutral beta-glucocerebrosidases.
Hayashi Y; Zama K; Abe E; Okino N; Inoue T; Ohno K; Ito M
Anal Biochem; 2008 Dec; 383(1):122-9. PubMed ID: 18708024
[TBL] [Abstract][Full Text] [Related]
34. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.
McEachern KA; Fung J; Komarnitsky S; Siegel CS; Chuang WL; Hutto E; Shayman JA; Grabowski GA; Aerts JM; Cheng SH; Copeland DP; Marshall J
Mol Genet Metab; 2007 Jul; 91(3):259-67. PubMed ID: 17509920
[TBL] [Abstract][Full Text] [Related]
35. Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease.
Serra-Vinardell J; Díaz L; Gutiérrez-de Terán H; Sánchez-Ollé G; Bujons J; Michelakakis H; Mavridou I; Aerts JM; Delgado A; Grinberg D; Vilageliu L; Casas J
Int J Biochem Cell Biol; 2014 Sep; 54():245-54. PubMed ID: 25084554
[TBL] [Abstract][Full Text] [Related]
36. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.
Sun Y; Liou B; Ran H; Skelton MR; Williams MT; Vorhees CV; Kitatani K; Hannun YA; Witte DP; Xu YH; Grabowski GA
Hum Mol Genet; 2010 Mar; 19(6):1088-97. PubMed ID: 20047948
[TBL] [Abstract][Full Text] [Related]
37. Identification of miRNAs that modulate glucocerebrosidase activity in Gaucher disease cells.
Siebert M; Westbroek W; Chen YC; Moaven N; Li Y; Velayati A; Saraiva-Pereira ML; Martin SE; Sidransky E
RNA Biol; 2014; 11(10):1291-300. PubMed ID: 25584808
[TBL] [Abstract][Full Text] [Related]
38. A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin.
Kinghorn KJ; Grönke S; Castillo-Quan JI; Woodling NS; Li L; Sirka E; Gegg M; Mills K; Hardy J; Bjedov I; Partridge L
J Neurosci; 2016 Nov; 36(46):11654-11670. PubMed ID: 27852774
[TBL] [Abstract][Full Text] [Related]
39. Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model.
Marshall J; McEachern KA; Kyros JA; Nietupski JB; Budzinski T; Ziegler RJ; Yew NS; Sullivan J; Scaria A; van Rooijen N; Barranger JA; Cheng SH
Mol Ther; 2002 Aug; 6(2):179-89. PubMed ID: 12161184
[TBL] [Abstract][Full Text] [Related]
40. Presence of activator proteins for the enzymatic degradation of glucosylceramide in several human tissues.
Vaccaro AM; Ciaffoni F; Mandara I; Suzuki K
Clin Chim Acta; 1988 Mar; 172(2-3):323-34. PubMed ID: 3370844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
